Muscle atrophy arises because of many chronic illnesses, as well as from prolonged glucocorticoid treatment and nutrient deprivation. We previously demonstrated that the USP19 deubiquitinating enzyme plays an important role in chronic glucocorticoid-and denervation-induced muscle wasting. However, the mechanisms by which USP19 exerts its effects remain unknown. To explore this further, we fasted mice for 48 hours to try to identify early differences in the response of wild-type and USP19 knockout (KO) mice that could yield insights into the mechanisms of USP19 action. USP19 KO mice manifested less myofiber atrophy in response to fasting due to increased rates of protein synthesis. Insulin signaling was enhanced in the KO mice, as revealed by lower circulating insulin levels, increased insulin-stimulated glucose disposal and phosphorylation of Akt and S6K in muscle, and improved overall glucose tolerance. Glucocorticoid signaling, which is essential in many conditions of atrophy, was decreased in KO muscle, as revealed by decreased expression of glucocorticoid receptor (GR) target genes upon both fasting and glucocorticoid treatment. This decreased GR signaling was associated with lower GR protein levels in the USP19 KO muscle. Restoring the GR levels in USP19-deficient muscle was sufficient to abolish the protection from myofiber atrophy. Expression of GR target genes also correlated with that of USP19 in human muscle samples. Thus, USP19 modulates GR levels and in so doing may modulate both insulin and glucocorticoid signaling, two critical pathways that control protein turnover in muscle and overall glucose homeostasis. (Endocrinology
L oss of skeletal muscle mass and function is a frequent complication of many common conditions such as cancer, heart and kidney failure, lung disease, as well as glucocorticoid therapy and aging. The loss of mass and impaired function result in weakness and decreased quality of life. Importantly, the muscle wasting independently predicts mortality as revealed, for example, in studies of patients with cancer (1), congestive heart failure (2), and chronic obstructive pulmonary disease (3) . Preclinical studies indicate that reversing the muscle wasting can prolong survival independent of any change in the underlying disease (4) . Therefore, understanding the underlying mechanisms regulating muscle wasting may lead to the design of therapies that could have considerable impact on the morbidity and mortality of many prevalent disorders.
Muscle wasting occurs because of increased rates of protein degradation and decreased rates of protein synthesis. Muscle protein is degraded via the two major proteolytic systems in the cell, the ubiquitin proteasome system and the autophagy-lysosomal system. During muscle atrophy, both systems are activated and play essential roles (5) . Components of the ubiquitin proteasome system are upregulated in muscle in many conditions of muscle wasting (6) (7) (8) . E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases act in series to conjugate ubiquitin to target substrates, thereby marking them for degradation or modulating their functions (9) . Importantly, two E3 ubiquitin ligases, MuRF-1 and MAFbx/Atrogin-1, are highly induced in atrophying muscle and allow for the disassembly and degradation of myofibrillar proteins (10, 11) . Inactivation of either MuRF1 or Atrogin-1 in mice blunts the musclewasting response and thus protects from atrophy (10, 12) . The autophagy-lysosomal system is also activated in skeletal muscle in various catabolic conditions and required for the maintenance of muscle mass (8, 13) .
Ubiquitination is a reversible process and also regulated by deubiquitinating enzymes (DUBs). In comparison with ubiquitin ligases, much less is known about the roles of DUBs in muscle atrophy. DUBs catalyze the cleavage of the bond formed between ubiquitin-ubiquitin or ubiquitin-substrate (14) . There are ;90 DUBs in the human genome classified into five families based on the homology of their catalytic domains (15) . DUBs could play a role in muscle atrophy by being downregulated under catabolic conditions, so that muscle proteins are more readily ubiquitinated and degraded. However, to date, no such DUB has been reported (16) . In contrast, we identified USP19 as a DUB that is upregulated under catabolic conditions in muscle, including the insulinopenic conditions of fasting and streptozotocin-induced diabetes, as well as cancer, glucocorticoid therapy (17) , and denervation (18) . Silencing of USP19 in muscle cells results in the increased expression of major myofibrillar proteins (19) consistent with USP19 negatively regulating muscle mass. Indeed, knockout (KO) of USP19 in mice protects against glucocorticoid-and denervationinduced muscle atrophy (20) . Additionally, silencing of USP19 in female mice leads to increased muscle mass and fiber size through estrogen receptor-dependent mechanisms (21) .
Although these recent studies demonstrate an important role for USP19 in muscle wasting, the molecular mechanisms by which it exerts its effects remain unknown. To explore this, we have examined the role of USP19 in fasting-induced muscle wasting. USP19 is induced in skeletal muscle upon fasting (17) , and nutritional insufficiency is often present in many diseases associated with muscle atrophy and so may contribute to the pathogenesis of the loss of muscle mass. Importantly, the metabolic changes induced upon fasting are rapid, and therefore, the analysis of these shorter time points may yield insights into early and more direct targets of USP19 action that are more difficult to dissect from longer-term models of atrophy that we previously studied, such as denervation and glucocorticoid therapy (20) . Indeed, we found that myofiber atrophy is reduced in USP19 KO mice upon fasting and that USP19 modulates insulin and glucocorticoid receptor (GR) signaling associated with a role in the catabolic response in skeletal muscle as well as in overall glucose homeostasis.
Materials and Methods

Animals
Animal studies were approved by the McGill University and McGill University Health Centre Research Institute Animal Care Committees in accordance with the guidelines of the Canadian Council on Animal Care. Mice were housed in highefficiency particulate air-filtered cages with a 12-hour day/night cycle. Heterozygous mice were mated to generate wild-type (WT) and USP19 KO littermates (20) . For fasting experiments, female mice (age 2 to 2.5 months) were food deprived for up to 48 hours. To avoid male cannibalism, female mice were used for fasting experiments. For glucocorticoid treatment, mice (age 5 months) were injected subcutaneously twice a day with dexamethasone (5 mg/kg). Hindlimb strength was measured using a Grip Strength Meter (Columbus Instruments, Columbus, OH) by taking the average of three trials at each time point.
Muscle protein synthesis
Muscle protein synthesis rates were measured before and after 48 hours of fasting by injecting mice with a flooding dose of L-[ring-d 5 ]-phenylalanine as described previously (22) . Mice were euthanized 30 minutes later, and the gastrocnemius muscle was collected and flash frozen in liquid nitrogen. Muscles were processed, and fractional synthesis rates of sarcoplasmic and myofibrillar proteins were determined by mass spectrometry (20) .
Glucose tolerance, insulin tolerance, and pyruvate tolerance tests and fasting insulin Mice were fasted for 16 hours overnight [glucose tolerance test (GTT), pyruvate tolerance test (PTT), and fasting insulin] or for 4 hours [insulin tolerance test (ITT)]. For GTT, ITT, or PTT, 2 mg/g glucose or 0.75 U/kg crystalline zinc insulin (Humulin R; Eli Lilly and Company) or 2 mg/g pyruvate was administered, respectively, to the mice intraperitoneally. Blood glucose was measured on a tail vein drop of blood using a glucometer (AccuChek; Roche, Mississauga, ON, Canada). For fasting insulin, blood was collected from the saphenous vein and allowed to clot. Serum insulin levels were measured with an insulin assay kit (Meso Scale Discovery, Rockville, MD). For measurement of insulin signaling in muscle, mice were fasted overnight and then injected with insulin as noted previously and euthanized 20 minutes later. Male mice were used in these metabolic studies as they are generally recognized to be more sensitive to changes in insulin sensitivity.
RNA analysis by quantitative PCR
RNA was prepared from tibialis anterior (TA) muscle by solubilization in 4 mol guanidine isothiocyanate and then ultracentrifugation through a CsCl cushion, followed by phenol-chloroform extraction and ethanol precipitation. RNA was quantified using a NanoDrop LITE spectrophotometer (Thermo Fisher Scientific, Waltham, MA). cDNA was synthesized from RNA (1 mg) using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA). Quantitative PCR analysis was done using SYBR-Green Master Mix on a ViiA7 machine with genespecific primers (Supplemental Table 1 ). Differences in target gene expression were analyzed using the DD threshold cycle method.
Immunoblotting
TA muscles were homogenized (Polytron; Kinematica, Lucerne, Switzerland) in cold radioimmunoprecipitation assay buffer with protease and phosphatase inhibitors (Roche, Mississauga, ON, Canada). The homogenate was spun in a refrigerated centrifuge at 17,500g for 15 minutes. The supernatant was collected (the soluble sarcoplasmic fraction), whereas the pellet was solubilized in 2% SDS in 50 mmol Tris followed by sonication (the insoluble myofibrillar fraction). C2C12 cells were lysed in ice-cold radioimmunoprecipitation assay buffer with added protease and phosphatase inhibitors. Protein concentration was determined by the BCA Micro Protein Assay (Thermo Fisher Scientific). Protein from the soluble (40 mg) or from the insoluble (20 mg) fraction was subjected to SDS-PAGE and transferred to 0.45-mm nitrocellulose membranes. Membranes were probed with primary antibodies phosphorylated (p-)Akt (T308) (23), p-Akt (S473) (24), Akt (25), p-p70 S6K (26), p70 S6K (27), p-Foxo1/3 (28), Foxo1 (29), GR (30), USP19 (31), and FK2 for ubiquitinated proteins (32) . Following primary antibody incubation, membranes were incubated with secondary antibodies conjugated to horseradish peroxidase and incubated with chemiluminescent substrate. Membranes were visualized with a ChemiDoc Touch and the signals quantified using Image Laboratory software (Bio-Rad, Mississauga, ON, Canada).
Cell culture
C2C12 myoblasts (female, obtained from American Type Culture Collection) were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (growth medium) at 37°C in 5% CO 2 . CRISPR-mediated KO of USP19 in myoblasts was generated as follows. Single guide RNAs targeting exons 3 (KO #1, 5 0 -AGGAAGCCCGAAC-CAGAAGCGG-3 0 ) and 22 (KO #2, 5 0 -ATGCATCAAAC-CGTGAGCAGCGG-3 0 ) were cloned into LeGO-U6-Cas9 vector using AgeI and SphI (New England Biolabs, Ipswich, MA). Lentiviruses were generated by cotransfecting the LeGO-U6-Cas9 plasmid with psPAX2 (12260; Addgene, Cambridge, MA) and pCMV-VSV-G (8454; Addgene) into 293T cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cells (8 3 10 6 ) were seeded together with DNA-liposome complex in DMEM medium supplemented with 10% FBS. Twenty-four hours later, the medium was changed to virus harvesting medium (DMEM, 10% FBS, and 2 mM L-glutamine). Virus supernatant was collected 48 hours posttransfection and concentrated 10-fold by ultracentrifugation at 110,000g for 3 hours. 
Human muscle gene expression correlation analysis
This study was approved by the Alberta Cancer Research Ethics Committee, and all patients provided written consent. The cohort consisted of male and female patients with abdominal cancers (Supplemental Table 3 ). Biopsies of rectus abdominis muscle (0.5 to 1 g) were taken from the site of incision at the time of surgery. Muscles were procured at the beginning of the operation by sharp dissection and then immediately snap frozen. Tissues were stored at the Alberta Cancer Research Biobank/Canadian Breast Cancer Foundation Tumour Bank (Cross Cancer Institute, Edmonton, AB, Canada) and the University of Calgary Comprehensive Gastrointestinal and Hepatopancreaticobiliary Tumor Bank (Calgary, AB, Canada). Processing of tissues and microarray analysis have been previously described in detail (20, 33) .
Electroporation studies
Under general anesthesia, an incision was made through the skin and subcutaneous fascia of the anterior surface of the leg of the mouse to expose the TA muscle. For silencing USP19, USP19 short hairpin RNA-expressing (40 mg; Thermo Fisher Scientific) clones V3LMM467881 (antisense sequence 5 0 -TCGTCTACTGTTGTCACCG-3 0 ) and V3LMM467877 (antisense sequence 5 0 -CGTCTACTGTTGTCACCGT-3 0 ) or control (clone RHS4346) plasmids were used. For expression of GR, a plasmid comprising a three times hemagglutinin and three times Flag-tagged GR in a PLNCX2 vector backbone was used (5 mg in CD1 mice and 10 mg in USP19 KO mice). To identify transduced fibers, 5 mg GFP-expressing plasmid was also included. The plasmids (in 25 to 30 mL of 0.9% saline) were injected into the TA muscle with a 31-gauge needle. One electrode was then placed between the muscle and the underlying bone and the other electrode on top of the muscle. Five pulses were delivered (21 V, 20-ms pulse length, and 200-ms pulse interval). After 1 week of recovery, the mice (age 2 to 2.5 months) were treated with dexamethasone (5 mg/kg) subcutaneously twice daily for 1 week to induce atrophy. At euthanization, the muscles were frozen in dry ice-chilled isopentane, sectioned, and viewed with a fluorescence microscope to identify GFP-positive fibers. The section was then fixed and stained with antidystrophin antibody to outline the borders of the myofibers.
Muscle fiber cross-sectional area analysis
Fiber cross-sectional areas (CSAs) were systematically analyzed using SMASH software (34) , analyzing the entire cross section of the TA muscle. For mice that were electroporated with plasmids expressing GR and GFP, the CSAs of all GFPpositive fibers were manually measured using ImageJ software (National Institutes of Health). The observer was blinded to the experimental condition during analysis.
Measurement of serum corticosterone levels
Blood was collected from WT and USP19 KO mice from the saphenous vein at 8:00 AM and 6:00 PM. Blood was allowed to clot and then was centrifuged at 2000g for 15 minutes at 4°C. Serum was aliquoted, and a corticosterone enzyme-linked immunosorbent assay (Cayman Chemical, Ann Arbor, MI) was performed on diluted serum as per the manufacturer's protocol.
Statistical analyses
Data are presented as mean 6 SEM unless otherwise indicated. Statistical analysis was performed using Prism 6 software (GraphPad). Analysis was done by Student t test if comparing a single parameter, one-way ANOVA (followed by post hoc Tukey test) if comparing multiple conditions, or two-way ANOVA if comparing multiple independent variables.
Results
Genetic inactivation of USP19 protects against muscle wasting induced by fasting Upon fasting, both WT and USP19 KO mice lost weight progressively with time with near identical kinetics (Fig. 1A) . To explore whether specific tissues might respond differently, we measured the changes in mass of the key tissues involved in the metabolic response to fasting ( Fig. 1B;  Supplemental Fig. 1 ). In the fed state, epididymal fat, liver, kidney, and heart were significantly smaller in the KO mice. In contrast, skeletal muscle masses were similar, suggesting a relative increase compared with the other major tissues (Supplemental Fig. 1 ). Upon fasting, there was similar atrophy in fat, liver, kidney, and heart in WT and KO mice. However, the skeletal muscle appeared to atrophy less in the KO mice, although this was noteworthy only in the TA muscle (Fig. 1B) . Importantly, this protection from atrophy was associated with improved strength, indicating that muscle function also benefited (Fig. 1C) . Because inducing muscle loss by food deprivation is a short intervention (48 hours), and the muscle loss seen upon fasting is small relative to other models of atrophy (20, 35) , we characterized this protection from muscle loss more fully by examining the CSAs of muscle fibers. In the TA muscle, we found that KO mice had significantly larger myofibers upon fasting ( Fig. 1D and 1E ).
USP19 genetic inactivation results in increased fractional synthesis rate in the muscle without changes in atrogene expression upon fasting
Because muscle consists mostly of myofibrillar proteins, we tested whether the improvement in myofiber size was due to improved protein synthesis or decreased protein degradation. Rates of protein synthesis fell as expected in both WT and KO mice upon fasting. However, the decrease in the KO mice was markedly smaller, and this was true for both the soluble sarcoplasmic proteins ( Fig. 2A) as well as the insoluble myofibrillar proteins (Fig. 2B) . Because it is not practical to measure rates of muscle protein degradation in vivo directly, we assessed the expression of markers of the ubiquitin and autophagy/lysosomal degradative systems that are both induced in muscle wasting (atrogenes). As previously demonstrated, the expression of MuRF1 and atrogin-1 are markedly increased upon fasting in WT mice (16, 36) . However, similar increases were seen in the KO mice (Fig. 2C) . Expression of the control gene GAPDH was unchanged under these conditions (Supplemental Fig. 2 ). We did not assess protein levels of these ubiquitin ligases, as our experience to date with these antibodies is that they are not very specific. Consistent with what we observed with MuRF1 and atrogin-1 expression, similar levels of protein ubiquitination were observed in WT and KO mice in both the sarcoplasmic and myofibrillar fractions ( Fig. 2D and 2E) . Nutrient deprivation is a powerful inducer of autophagy. Consistent with this, we observed increased levels of lipidated LC3 upon fasting, but there was no difference between WT and KO (Fig. 2F) . Additionally, there was marked induction of genes in the autophagy pathway-LC3, Atg4, and Gabarap-but this was also similar in both WT and KO muscles (Fig. 2G) . Thus, the protection from myofiber atrophy appears to be primarily due to a higher level of protein synthesis in the fasted state.
Genetic inactivation of USP19 results in mice that are more insulin sensitive
Because the metabolic response to fasting in muscle is largely mediated by decreases in levels of insulin, we measured these levels in the mice. Fasting insulin levels were ;70% lower in the KO mice (Fig. 3A) . Glucose levels were similar in the WT and KO mice, suggesting that the KO mice had markedly improved insulin sensitivity (Fig. 3B) . To explore this further, we tested the glucose-lowering effects of insulin. When insulin was given to WT and KO mice, the KO mice demonstrated a greater decrease in blood glucose levels than the WT mice (Fig. 3C ). This suggested that the KO mice might also have better glucose tolerance. Indeed, the glucose excursion following glucose administration was significantly lower in the KO mice (Fig. 3D) . Additionally, hepatic glucose output evaluated as the rise in glucose after pyruvate administration was significantly lower in USP19 KO mice (Fig. 3E) . Thus, the loss of USP19 provokes improvements in insulin sensitivity.
Genetic inactivation of USP19 results in enhanced insulin signaling in muscle
To assess whether this improved insulin sensitivity was reflected at the cellular level, we tested whether insulin signaling was increased upon insulin administration. Indeed, activation of Akt, a critical node in the insulin-signaling pathway, was significantly increased upon insulin administration in KO mice compared with WT mice (Fig. 4A and  4B ). Because we saw enhanced rates of protein synthesis in the KO mice, we assessed whether p70 S6K , an important modulator of protein synthesis downstream of Akt, is more activated in the muscle of these mice. Indeed, levels of p-p70 S6K normalized to total p70 S6K were higher in the KO mice ( Fig. 4A and 4B) . No increase in 4EBP1 phosphorylation was observed in the KO mice. Other important mediators of insulin action downstream of Akt are the FoxO1 and FoxO3 transcription factors. When phosphorylated, they are retained in the cytoplasm and inactive. However, when insulin levels are low, these proteins are nonphosphorylated, translocate to the nucleus, and activate genes that play important roles in the metabolic response to fasting. These genes include the ubiquitin ligases MuRF1 and atrogin-1 and multiple autophagy genes in skeletal muscle. We therefore assessed whether the phosphorylation , phosphorylation of FoxO was similar in the WT and KO tissues following insulin administration ( Fig. 4A and 4B ). The absence of notable differences in FoxO phosphorylation was consistent with the absence of changes in MuRF1, atrogin-1, and autophagy genes. Finally, to address whether the loss of USP19 affects muscle insulin signaling in a cell-autonomous manner, we inactivated the USP19 gene in muscle cells using CRISPR-Cas9 technology. Consistent with what we observed in vivo, KO cells showed enhanced activation of Akt by insulin (Fig. 4C and 4D ).
Genetic inactivation of USP19 results in decreased glucocorticoid signaling
To assess how USP19 may be modulating insulin signaling, we assessed if USP19 was doing so through the regulation of glucocorticoid signaling. Glucocorticoids are known to be essential for the metabolic response to fasting and can modulate insulin sensitivity as well as negatively regulate insulin signaling (37) (38) (39) . We determined whether glucocorticoid target genes (chosen based on evidence that they are direct targets of and regulated by GR in muscle) were differentially expressed in KO muscle compared with WT. Many of the glucocorticoid target genes were upregulated upon fasting, consistent with the important role for these hormones in mediating the response to caloric deprivation (Supplemental Fig. 3) . Interestingly, 7 of the 12 genes-Lcn2, Odf3l2, Ces1d, Grb10, Pi3kr1, Ddit4, and Fkbp5-were significantly downregulated in the KO muscle from fasted mice (Fig. 5A) , suggesting that indeed glucocorticoid signaling is decreased. To confirm this, we evaluated the expression of these genes in WT and KO muscle from mice treated with glucocorticoids. Of the 12 genes tested, 8 were significantly differentially regulated between WT and KO mice, including Lcn2, Odf3l2, Ces1d, Cblb, Ddit4, Klf15, Fkbp4, and Foxo3 (Fig. 5B) . Levels of the GAPDH control mRNA did not change significantly under these conditions (Supplemental Fig. 2 ). To ensure that this decrease in glucocorticoid signaling in the KO muscle was not due to decreased circulating hormone, we measured corticosterone levels at the peak (late afternoon) and trough (early morning) periods. Indeed, we observed similar corticosterone levels in WT and KO during the peak period and slightly increased corticosterone levels in the KO during the trough period (Supplemental Fig. 4) . Thus, the loss of USP19 results in decreased glucocorticoid signaling. To explore whether this regulation may be relevant in human skeletal muscle, we examined whether the expression of these GR target genes correlates with that of USP19 in muscle samples obtained from patients undergoing surgery for abdominal cancers, which commonly cause muscle atrophy (Supplemental Table 2 ). Indeed, mRNA levels of 9 out of the 12 genes were significantly correlated to levels of USP19 mRNA ( Fig. 5C ; Table 1 ; Supplemental Fig. 5 ).
USP19 mediates its effects on muscle wasting through the GR
To address how USP19 might be mediating its effects on glucocorticoid signaling, we tested whether USP19 might modulate proteins involved in the signaling. We began by examining levels of the GR itself and found 50% lower levels of the protein in the muscle of KO mice as well as in differentiated KO muscle cells (Fig. 6A) . Interestingly, there was no difference in the mRNA levels of GR in the muscle, indicating that the regulation of GR in the KO muscle is happening posttranscriptionally (Fig. 6B) . Indeed, our recent preliminary studies indicate that GR is degraded more rapidly in cultured muscle cells lacking USP19 (data not shown). We then asked whether these decreased levels of GR in the USP19-deficient muscle were responsible for the protection from muscle atrophy. To test this, we electroporated a GR-expressing plasmid into one TA muscle of KO mice and determined whether the muscle with restored GR was more prone to dexamethasone-induced atrophy. Dexamethasone was chosen as a catabolic stimulus instead of fasting because the atrophy induced by 1 week of dexamethasone is much larger than that seen upon 2 days of fasting, and USP19 KO mice are also protected from dexamethasone-induced atrophy (20) . Indeed, expressing GR in the KO muscle resulted in dexamethasone-induced atrophy of myofibers that was now indistinguishable from that seen in the WT mice treated with the glucocorticoid (Fig. 6C-6E) . Thus, the decreased GR in the KO muscle is able to explain the protection from atrophy observed in these mice. To test this another way and to assess if the effect of USP19 is tissue/cell autonomous, we electroporated plasmids expressing short hairpins against USP19 into the TA muscle of CD1 mice and then subjected the mice to 1 week of dexamethasone treatment. Muscles expressing the short hairpin RNA plasmids against USP19 had significantly larger muscle fiber CSAs after treatment with dexamethasone, indicating that indeed the larger muscles seen in the USP19 KO mice are due at least in part to USP19 action in the muscle (Supplemental Fig. 6A) . Next, to confirm whether expression of GR would reverse the protective effect of silencing USP19, both TA muscles of CD1 mice were electroporated with plasmids with short hairpins against USP19 to reduce the level of USP19. One leg was also electroporated with a GR-expressing plasmid, whereas the other leg was electroporated with an empty (B) Glucocorticoid target gene expression in the TA muscle after 1 wk of twice-daily dexamethasone treatment (5 mg/kg) (WT, n = 10; KO, n = 10 male mice). (C) Correlation between USP19 mRNA and GR target gene (DDIT4 and PI3KR1) mRNA levels (arbitrary units) in human muscle biopsies from patients with abdominal cancers. *P , 0.05; **P , 0.01.
vector as a paired control, and the mice were subjected to dexamethasone treatment. GR protein levels were only mildly increased in muscles that were electroporated with a plasmid expressing GR compared with those that were electroporated with an empty vector plasmid, indicating that GR was not markedly overexpressed (Supplemental Fig. 6B ). We observed that the average CSAs of muscle fibers of mice in which short hairpin USP19 (shUSP19) and GR were both expressed were significantly smaller than muscle fibers with just shUSP19 expression ( Fig. 6F and  6G) . We also observed a shift in the fiber size distribution of GFP + fibers to smaller fibers, confirming the finding that expressing GR in the absence of USP19 reverses the protection from muscle atrophy (Fig. 6F and 6G ).
Discussion
In this report, we describe mechanistic insights into the regulation of muscle mass by USP19. This DUB regulates insulin and glucocorticoid signaling, two critical pathways that modulate protein turnover (Fig. 7) . Insulin and the related hormone IGF-1 promote protein synthesis and suppress protein degradation through activation of the Akt-mammalian target of rapamycin (mTOR) and the Akt-FoxO pathways, respectively. In this study, we showed that KO of USP19 results in increased insulinstimulated phosphorylation of Akt and p70 S6K , with no effect on p-FoxO. Consistent with the role of p70 S6K in the activation of translation, we observed increased rates of synthesis of both sarcoplasmic and myofibrillar fractions in the KO muscle, suggesting that USP19 regulates a global protein synthesis pathway rather than the synthesis of very specific proteins. FoxO1/3 activates transcription of the key ubiquitin ligases MuRF1 and atrogin-1/MafBx as well as genes in the autophagic system (40) . The lack of evident differences in insulinstimulated phosphorylation of FoxO can explain the lack of change in levels of these two ligases and of multiple markers of autophagy, including levels of lipidated LC3 in the fasted KO muscle.
In addition to insulin signaling, we show that USP19 modulates glucocorticoid signaling (Fig. 5) . The production of glucocorticoids is increased in many illnesses, and this class of hormones is also frequently used therapeutically for suppression of immunity or inflammation; so, excess glucocorticoids play an important role in many forms of muscle wasting (41, 42) . Indeed, the activation of muscle protein breakdown by a number of diverse catabolic stimuli (43) (44) (45) can be blocked or blunted by interfering with the production or action of glucocorticoids. Glucocorticoids suppress muscle protein synthesis and also have a permissive effect on activation of protein degradation (46, 47) . Thus, the decreased expression of glucocorticoid target genes in the fasted KO muscle is highly consistent with improved muscle mass from decreased glucocorticoid action. Interestingly, we found that mRNA levels of the GR target gene Ddit4 (REDD1) are lower in our KO mice. REDD1 acts by sequestering 14-3-3 proteins, thereby releasing and increasing the ability of TSC1/2 to inhibit mTOR (48, 49) . Also, upstream of mTOR is Akt, a kinase responsible for its activation. The GR target gene Pi3kr1 (p85a) is the regulatory subunit of phosphatidylinositol 3-kinase (PI3K), which, when expressed at high levels, acts as a dominant negative, thereby inhibiting PI3K activity and decreasing Akt activation. In the fasting model, we see decreased expression of Pi3kr1, increased phosphorylation of Akt, and decreased Ddit4 (REDD1) mRNA expression in the KO consistent with overall mTOR complex 1 activation (Figs. 4 and 5) . Additionally, GR can competitively bind to PI3K, reducing its association with insulin receptor substrate 1 and negatively regulating signaling (45) . The decreased GR protein observed in the KO mice would result in less GR binding to PI3K and therefore increased signaling and activation of Akt. These pathways converging at mTOR could (Fig. 7) . The previously mentioned effects of USP19 on muscle protein synthesis in the fasted state are in contrast to what is observed in glucocorticoid-induced muscle atrophy, in which USP19 KO reduces the upregulation of the atrogenes but has no effect on the rates of protein synthesis (20) . The altered balance between protein synthesis and protein degradation pathways in USP19 KO mice in different models of atrophy could be explained, at least in part, by differences in expression of Klf15, a transcriptional activator of both FoxO and several atrogenes (50) (Fig. 5) . In fasting-induced muscle atrophy, the expression of Klf15 is unchanged between WT and KO mice, suggesting that the activation of FoxO and atrogenes upon fasting might be similar (Fig. 7) , which is indeed what we observed in this study. This unchanged Klf15 expression coupled with decreased Ddit4 and Pi3kr1 expression could allow for increased activation of mTOR and increased rates of protein synthesis. Conversely, in dexamethasone-induced muscle atrophy, we see decreased levels of Klf15 expression in the KO mice, suggesting that the activation of the atrogenes would be decreased, which is what we observed previously (20) . This, coupled with the unchanged Pi3kr1 levels in the dexamethasone-treated KO muscle, would favor modulation of protein degradation pathways over changes in protein synthesis. Thus, upon both fasting and dexamethasone treatment, there are decreases in expression of glucocorticoid target genes in the KO muscle that can explain the improved muscle mass. However, the patterns of regulated target genes are not identical between fasting and dexamethasone treatment, and the differences can explain the changes in protein synthesis in the former and in proteolysis in the latter.
The improvement in insulin signaling in our KO mice extended beyond effects on muscle protein turnover. Muscle is the major site of insulinstimulated glucose uptake, and we observed enhanced glucose lowering when insulin was administered to the KO mice. Glucose tolerance was significantly better in the KO mice, consistent with improved glucose disposal. Fasting insulin levels were also markedly lower in the KO mice in the presence of near-identical glucose levels, indicating whole-body improvement in insulin sensitivity. It will be of interest to explore in future studies beta cell mass as well as function in the KO mice. The KO mice also manifested smaller rises in glucose levels after administration of pyruvate, suggesting that hepatic glucose production is also decreased in the KO. This opens the possibility that USP19 may be important for insulin signaling in other key metabolic tissues beyond the muscle. The overall improvement in insulin sensitivity and in glucose tolerance also suggest potential roles for USP19 in modulating insulin resistance and the development of diabetes, respectively. Indeed, our recent studies indicate that USP19 KO mice have decreased fat mass and are more sensitive to insulin and more glucose tolerant than WT mice upon high-fat feeding (unpublished data).
Insulin and glucocorticoids play important roles in the metabolic response to fasting, particularly in the regulation of the breakdown of muscle proteins to supply amino acids to the liver for gluconeogenesis (38) . The altered signaling in these pathways that we observed would predict less negative protein balance upon fasting, and indeed we demonstrated that the genetic inactivation of USP19 offers protection from food deprivation-induced decreases in muscle mass and function. Nutrient insufficiency due to loss of appetite is found in many chronic conditions as well as aging and so likely contributes significantly to the overall burden of muscle wasting (51) . We previously showed that loss of USP19 protects from muscle wasting induced by denervation and glucocorticoid treatment (20) . Thus, this work provides further evidence that pharmacological inhibition of USP19 could be a beneficial approach in the treatment of muscle-wasting disorders, including the muscle atrophy associated with nutritional insufficiency. The correlation of USP19 expression with that of GR target genes in skeletal muscle from patients with cancer ( Fig. 5C; Supplemental Fig. 5) suggests that the regulatory mechanism we have observed is in fact conserved in humans. Figure 7 . Model of USP19 action in muscle wasting. USP19 is upregulated in skeletal muscle in catabolic conditions, and this upregulation leads to increased GR protein levels. The increase in GR protein promotes increased expression of GR target genes such as Pi3kr1 (P85a), Klf15, and Ddit4, which result in the negative regulation of insulin-Akt-mTOR signaling and the upregulation of atrogenes, ultimately resulting in muscle atrophy from enhanced protein degradation and/or suppressed protein synthesis.
